Appeal No. 2006-2466 Page 7 Application No. 09/835,759 challenged with MUC1+3T3 cells, had poor tumor protection; significant antibody titers were produced, a detectable CD4+ DTH [delayed-type hypersensitivity], but no CTL [cytotoxic T cells] were found.’ (see page 930, right column).” Examiner’s Answer, page 11. In addition, Tachibana teaches that the “combined treatment with cyclophosphamide (an immunosuppressant to depress humoral response and/or regulatory cells; see page 456) plus hybrid cells showed no antibody elevation and immune complex production, but generation of potent cytotoxic T cells was comparable to that of immunized hosts and was followed by curative antitumor effect (see page 461).” Id., page 12. Furthermore, Parkhouse teaches “that normal B cells bear surface CD22 and an anti-CD22 antibody-ricin conjugate effectively depletes normal B cells (see Figure 3).” Id. The examiner argues that, in view of the applied references, “one of ordinary skill in the art would have been motivated and had a reasonable expectation of success at the time the invention was made to . . . produce a composition . . . comprising a tumor- associated antigen (i.e., MUC1) and the anti-CD22 antibody-ricin conjugate of Parkhouse et al[.] for depleting B cells.” Id., page 16. In particular, the examiner argues that: The motivation to make the above modifications is made explicit in the teachings of Apostolopoulos et al[.] who teach that induction of a humoral immune response (i.e., TH2 or antibody response) gives poor tumor protection accompanied by little cellular immunity and [that] induction of a cellular immune response (i.e., TH1 response) results in significant tumor protection, cytotoxic T lymphocytes and little antibody production (i.e., TH2 or humoral immune response) (see abstract). Additional motivation for the above modifications and in agreement with Apostolopoulos et al[.], Tachibana et al[.] state “[that] enhancement of tumor growth was caused by acceleration of humoral response existing beforehand in the tumor-bearing state” (see pg. 461). Therefore, one ofPage: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 NextLast modified: November 3, 2007